364 related articles for article (PubMed ID: 32705243)
1. SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non‑small cell lung cancer.
Li J; Zhao L; Pan Y; Ma X; Liu L; Wang W; You W
Int J Oncol; 2020 Sep; 57(3):756-766. PubMed ID: 32705243
[TBL] [Abstract][Full Text] [Related]
2. COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance.
Shen L; Yang M; Lin Q; Zhang Z; Zhu B; Miao C
Oncol Rep; 2016 Aug; 36(2):877-85. PubMed ID: 27373316
[TBL] [Abstract][Full Text] [Related]
3. CHAF1B promotes proliferation and reduces apoptosis in 95‑D lung cancer cells and predicts a poor prognosis in non‑small cell lung cancer.
Duan Y; Liu T; Li S; Huang M; Li X; Zhao H; Li J
Oncol Rep; 2019 Apr; 41(4):2518-2528. PubMed ID: 30720130
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of microRNA-1303 is a potential prognostic marker of non-small cell lung cancer.
Chen J; Jiang T; Yu B; Li T; Zhao P; Yuan L; Qi J
Cancer Biomark; 2020; 28(4):439-446. PubMed ID: 32508320
[TBL] [Abstract][Full Text] [Related]
5. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma.
Zhu Y; Zhu MX; Zhang XD; Xu XE; Wu ZY; Liao LD; Li LY; Xie YM; Wu JY; Zou HY; Xie JJ; Li EM; Xu LY
Hum Pathol; 2016 Jun; 52():153-63. PubMed ID: 26980013
[TBL] [Abstract][Full Text] [Related]
6. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA OSER1‑AS1 promotes the malignant properties of non‑small cell lung cancer by sponging microRNA‑433‑3p and thereby increasing Smad2 expression.
Liu X; Huang S; Guan Y; Zhang Q
Oncol Rep; 2020 Aug; 44(2):599-610. PubMed ID: 32627026
[TBL] [Abstract][Full Text] [Related]
8. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
9. SMYD3 regulates the abnormal proliferation of non-small-cell lung cancer cells via the H3K4me3/ANO1 axis.
Zhong D; Zhan Z; Zhang J; Liu Y; He Z
J Biosci; 2022; 47():. PubMed ID: 36222132
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer.
Huang Y; Ni R; Wang J; Liu Y
Biomed Pharmacother; 2019 Jan; 109():1851-1859. PubMed ID: 30551440
[TBL] [Abstract][Full Text] [Related]
11. Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p.
Luo S; Shen M; Chen H; Li W; Chen C
Mol Med Rep; 2020 Nov; 22(5):3822-3832. PubMed ID: 32901838
[TBL] [Abstract][Full Text] [Related]
12. FOXD1 Promotes Cell Growth and Metastasis by Activation of Vimentin in NSCLC.
Li D; Fan S; Yu F; Zhu X; Song Y; Ye M; Fan L; Lv Z
Cell Physiol Biochem; 2018; 51(6):2716-2731. PubMed ID: 30562753
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of circular RNA hsa_circ_000984 promotes cells proliferation and metastasis in non-small cell lung cancer by modulating Wnt/β-catenin pathway.
Li XY; Liu YR; Zhou JH; Li W; Guo HH; Ma HP
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3366-3374. PubMed ID: 31081091
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the SMYD3 Promotes Proliferation, Migration, and Invasion of Pancreatic Cancer.
Zhu CL; Huang Q
Dig Dis Sci; 2020 Feb; 65(2):489-499. PubMed ID: 31441002
[TBL] [Abstract][Full Text] [Related]
15. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
[TBL] [Abstract][Full Text] [Related]
16. Nucleolar and spindle‑associated protein 1 promotes non‑small cell lung cancer progression and serves as an effector of myocyte enhancer factor 2D.
Ling B; Wei P; Xiao J; Cen B; Wei H; Feng X; Ye G; Li S; Zhang Z; Liang W; Huang S; Huang W
Oncol Rep; 2021 Mar; 45(3):1044-1058. PubMed ID: 33650655
[TBL] [Abstract][Full Text] [Related]
17. Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.
Wang Y; Xie BH; Lin WH; Huang YH; Ni JY; Hu J; Cui W; Zhou J; Shen L; Xu LF; Lian F; Li HP
Oncogene; 2019 Jun; 38(25):4948-4961. PubMed ID: 30842588
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of lncRNA EGFR‑AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non‑small cell lung cancer.
Xu YH; Tu JR; Zhao TT; Xie SG; Tang SB
Int J Oncol; 2019 Jan; 54(1):295-305. PubMed ID: 30431074
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-629 promotes the tumorigenesis of non-small-cell lung cancer by targeting FOXO1 and activating PI3K/AKT pathway.
Zhu L; Chen Y; Liu J; Nie K; Xiao Y; Yu H
Cancer Biomark; 2020; 29(3):347-357. PubMed ID: 32716350
[TBL] [Abstract][Full Text] [Related]
20. BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells.
Zhou X; Sun T; Meng Y; Luo J; Chen J; Xia B; Zhang Z; Cheng Z; Wang X
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
